DJIA 17,039.49 60.36 0.36%
NASDAQ 4,532.10 5.62 0.12%
S&P 500 1,992.37 5.86 0.29%
market minute promo

Ophthotec (NASDAQ: OPHT)

36.51 -1.75 (-4.57%)

Quote as of

company name or ticker

Recent Quotes

OPHT $36.51 -4.57%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $38.17
Previous Close $38.26
Daily Range $36.26 - $38.17
52-Week Range $22.61 - $47.99
Market Cap $1.2B
P/E Ratio 9.99
Dividend (Yield) $0.00 (0.0%)
Volume 216,439
Average Daily Volume 191,623
Current FY EPS -$2.88



Ophthotec (OPHT) Description

Ophthotech Corp is a biopharmaceutical company specializing in the development of novel therapeutics to treat diseases of the back of the eye with a focus on developing therapeutics for age-related macular degeneration. Website:

News & Commentary Rss Feed

3 Future Biotechnology Blockbusters?

Medivation, Ophthotech, and Portola all have potential blockbusters on their hands.

Ophthotech's (OPHT) CEO David Guyer on Q2 2014 Results - Earnings Call Transcript

Benzinga's Top Initiations

Roundtable: 3 Stocks Janet Yellen Is Dead Wrong About

The Fed thinks biotech stocks are overvalued. Here's where they're wrong.

Is Opthotech Your Next Multibagger Stock?

Opthotech is working on a treatment for wet AMD that could have sales potential equal to that of Novartis' Lucentis or Regeneron's (REGN) Eylea.

Ohr Pharmaceutical: Questionable Analyst Activity

Phase II Calamity Dooms Ohr's Eye Drops

3 Stocks Near 52-Week Highs Worth Selling

Are these three stocks sells or belles? You be the judge!

May's 3 Best Biotech Stocks

Here's what you need to know about MannKind, Itrexon, and Opthotech's soaring share prices in May.

Why Ophthotech (OPHT) Could Be Positioned for a Surge? - Tale of the Tape

Why Ophthotech (OPHT) Could Be Positioned for a Surge? - Tale of the Tape

See More OPHT News...